Inactive Instrument

Pardes Biosciences, Inc. Stock

PRDS

US69945Q1058

Chart Pardes Biosciences, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Pardes Biosciences, Inc.

Pardes Biosciences Goes Public Following Merger With Blank Check Firm FS Development	21-12-27	MT
FS Development Corp. II(NasdaqCM:FSII) dropped from NASDAQ Composite Index	21-12-24	CI
Pardes Biosciences, Inc. completed the acquisition of FS Development Corp. II from FS Development Holdings II, LLC, Daniel Dubin, Owen Hughes, Deepa Pakianathan, and others in a reverse merger transaction.	21-12-22	CI
FS Development Corp. II Registration Statement for Merger with Pardes Declared Effective by SEC	21-12-01	MT
FS Development Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
FS Development II : Pardes Biosciences Starts Phase 1 Study On Potential COVID-19 Treatment Ahead Of Merger With FS Development	21-08-26	MT
Fs Development Corp. Ii Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
FS Development II : Blank-Check Firm FS Development II to Merge With Pardes Biosciences	21-06-29	MT
Pardes Biosciences, Inc. entered into a definitive merger agreement to acquire FS Development Corp. II from FS Development Holdings II, LLC, Daniel Dubin, Owen Hughes, Deepa Pakianathan, and others for approximately $320 million in a reverse merger transaction.	21-06-28	CI
Fs Development Corp. Ii Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
FS Development Corp. II Announces Appointment of Directors	21-02-19	CI
FS Development Corp. II announced that it has received $6.025 million in funding from FS Development Holdings II, LLC	21-02-18	CI
FS Development Corp. II(NasdaqCM:FSII) added to NASDAQ Composite Index	21-02-18	CI
FS Development Corp. II has completed an IPO in the amount of $175 million.	21-02-16	CI
FS Development Corp. II has filed an IPO in the amount of $100 million.	21-01-26	CI

More news

Press releases Pardes Biosciences, Inc.

FS II : Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19 - Form 8-K	21-12-27	PU
PARDES BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	21-12-27	AQ
PARDES BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)	21-12-23	AQ
FS DEVELOPMENT CORP. II : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	21-12-23	AQ
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections	21-12-21	BU

More press releases

FS Development Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It intends to identify opportunities in the biotechnology and life science infrastructure sector. It conducts no operations and generates no revenues.

Sector

More about the company